Diagnosis and Prognostic Assessment of Drug-Induced Liver Injury: What Are the Outpatient Options? (Review)

QR Code

Diagnosis and Prognostic Assessment of Drug-Induced Liver Injury: What Are the Outpatient Options? (Review)

INTRODUCTION. Drug-induced liver injury (DILI) is a common and potentially life-threatening complication associated with the use of medicinal products and bioactive dietary supplements. Recognising early signs of liver damage can be challenging for a number of reasons, including polypharmacy, comorb...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. V. Gantsgorn, A. V. Bozhko, S. V. Yarchenko
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2025-04-01
Series:	Безопасность и риск фармакотерапии
Subjects:	drug-induced liver injury hepatotoxity outpatient treatment early diagnosis adverse drug reaction cioms/rucam scale safety of pharmacotherapy risk factors drug monitoring
Online Access:	https://www.risksafety.ru/jour/article/view/447
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Polymorphism of genes and drug-induced liver injury
by: P. Ye. Tkachenko, et al.
Published: (2013-09-01)

Antibiotic-Associated Drug-Induced Liver Injury in Critically Ill Children: A Prospective Observational Study
by: A. V. Vlasova, et al.
Published: (2024-07-01)

Explaining Uncertain Hepatoprotective Effects: When Silibinin Co-Administered with Other Drugs
by: Dong Pu, et al.
Published: (2025-06-01)

Methodology for Creating a Risk Management System for Drug-Drug Interactions
by: A. A. Taube, et al.
Published: (2024-03-01)

Drug-induced bradycardia as a medical and social problem: data from the Cardiac Drug Overdoses Hospital Registry (STORM)
by: N. N. Nikulina, et al.
Published: (2020-08-01)

Risks of Oral Methotrexate Administration in Outpatients
by: Maria Ganeva, et al.
Published: (2014-11-01)

Predicting the risk of developing drug-induced liver injury during remdesivir therapy in COVID-19 patients using machine learning
by: Yu. V. Shevchuk, et al.
Published: (2024-12-01)

Results of Surveying Cardiologists and Clinical Pharmacologists on the Selection and the Efficacy and Safety Evaluation of Pharmacotherapy for Cardiovascular Diseases
by: Yu. R. Bolsunovskaya, et al.
Published: (2022-12-01)

Atrial Fibrillation Associated with Anticancer Drugs
by: O. D. Ostroumova, et al.
Published: (2020-12-01)

Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19
by: V. I. Petrov, et al.
Published: (2024-10-01)

Clinical and pharmacological monitoring of drug safety in pediatrics
by: N. V. Verlan, et al.
Published: (2016-05-01)

Drug-Induced Liver Injuries (Clinical Guidelines for Physicians)
by: Vladimir T. Ivashkin, et al.
Published: (2019-03-01)

EVALUATIONS OF ADVERSE DRUGS REACTIONS IN RUSSIA IN 2013
by: V. A. Merkulov, et al.
Published: (2022-05-01)

Drug-Induced Acute Kidney Injury
by: E. V. Zakharova, et al.
Published: (2021-10-01)

Effect of Genetic Polymorphism of the Enzyme Genes Responsible for Biotransformation of Antituberculous Drug on the Risk of Hepatotoxic Reaction in Patients with Tuberculosis
by: A. V. Kazakov, et al.
Published: (2020-05-01)

Review of the monograph by Kolbin A. S., Zyryanov S. K., Belousov D. Yu. "Pharmacovigilance" 2025
by: V. I. Petrov
Published: (2025-01-01)

Hepatotoxicity Associated with Adalimumab in Hidradenitis Suppurativa: A Report of Two Cases of Drug-Induced Liver Injury
by: Cristian Fernando Caballero-Linares, et al.
Published: (2025-07-01)

Drug-Induced Neutropenia and Agranulocytosis
by: O. D. Ostroumova, et al.
Published: (2020-09-01)

MONITORING OF DRUG SAFETY IN CLINICAL PRACTICE
by: N. V. Verlan, et al.
Published: (2017-02-01)

liver disease. Clinical case of liver cirrhosis against the background of non-steroidal anti-inflammatory drugs
by: E. Yu. Plotnikova, et al.
Published: (2021-06-01)

Drug-Induced Fatty Liver Disease
by: A. P. Pereverzev, et al.
Published: (2020-06-01)

Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
by: V. G. Deriushkin, et al.
Published: (2021-02-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
by: E. N. Tkhoseva, et al.
Published: (2022-06-01)

KNOWLEDGE, ATTITUDE AND PRACTICE AMONG HEALTHCARE PROFESSIONALS TOWARDS ADR REPORTING IN ABBOTTABAD PAKISTAN
Published: (2021-12-01)

WHAT TO DO WITH A VARIETY OF TERMS THAT REFLECT THE HARM OF DRUGS?
by: Yu. V. Muravyev, et al.
Published: (2017-04-01)

Idiosyncratic Drug-Induced Liver Injury: From Pathogenesis to Risk Reduction
by: I. A. Mazerkina
Published: (2023-06-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
by: Yu. V. Muravyev
Published: (2017-09-01)

On the safety of acetaminophen
by: R. N. Alyautdin, et al.
Published: (2022-06-01)

EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE
by: M. N. Kostyleva, et al.
Published: (2015-03-01)

Role of Pharmacovigilance in Drug Safety Monitoring
by: Anju E. Paul, et al.
Published: (2025-07-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
by: S. K. Zyryanov, et al.
Published: (2020-05-01)

The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study
by: V. I. Petrov, et al.
Published: (2025-06-01)

Female Gender as a Risk Factor for the Development of Drug-Induced Diseases
by: D. A. Sychev, et al.
Published: (2021-07-01)

Causes, Predisposing Factors and Prevention Directions of Drug-induced Bradycardia (Based on the Results of the Hospital Register of Oardiac Medications Overdoses STORM)
by: N. N. Nikulina, et al.
Published: (2021-07-01)

Pharmacological correction of hepatotoxicity induced by anti-tuberculosis drugs
by: D. S. Sukhanov, et al.
Published: (2023-04-01)

Potentially Inappropriate Medications for Use in Older Adults: Beers Criteria (2023 American Geriatrics Society Guidelines)
by: D. A. Sychev, et al.
Published: (2024-10-01)

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
by: V. I. Petrov, et al.
Published: (2022-04-01)

FALLING OF SENILE AGE PATIENT AS AN ADVERSE EVENT ASSOCIATED WITH THE USE OF MEDICINES: CASE REPORT
by: E. S. Ilina, et al.
Published: (2017-05-01)

“Implementing the pharmacovigilance system and publishing this journal, we were helping healthcare providers cultivate the sense of professional and civic responsibility”
by: V. K. Lepakhin, et al.
Published: (2024-04-01)

Advanced Age as a Risk Factor of Drug-Induced Diseases
by: D. A. Sychev, et al.
Published: (2021-03-01)